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Post-transcriptional regulation of 3-hydroxy-3-methylglutaryl coen-
zyme A reductase and cholesterol 7-hydroxylase in rats with subtotal
nephrectomy. Chronic renal failure is associated with hyperlipidemia and
atherosclerosis. The mechanism responsible for the observed increase of
serum cholesterol in chronic renal disease is not certain. The objective of
the present study was to characterize the effect of induced renal failure on
3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-C0A reductase)
and cholesterol 7a-hydroxylase, the two rate determining enzymes of the
cholesterol and bile acid biosynthetic pathways, respectively. Studies were
carried out in rats with subtotal (75%) nephrectomy, which resulted in a
marked elevation of blood urea nitrogen (371 44% of control, P <
0.001), and was accompanied by significant increases in the levels of serum
cholesterol (133 7%, P < 0.005) and triglycerides (185 25,P < 0.01).
In nephrectomized rats, an increase in the specific activity of HMG-CoA
reductase (219 30% above control levels, P < 0.02) was observed. This
increase occurred in the presence of elevated hepatic microsomal choles-
terol concentrations (150 13% of controls, P < 0.01). Surprisingly, the
increase in HMG-CoA reductase specific activity was not associated with
parallel increases in HMG-CoA reductase steady-state mRNA levels and
gene transcriptional activity. These uremic rats also exhibited a marked
increase in the specific activity of cholesterol 7a-hydroxylase (240 559%
of controls, P < 0.05). There was no concomitant increase in cholesterol
7a-hydroxylase steady-state mRNA levels or gene transcriptional activity.
The factors responsible for the observed increases in HMG-CoA reduc-
tase and cholesterol 7n-hydroxylase specific activity in renal failure remain
to be determined. In summary, renal failure induced by subtotal nephrec-
tomy results in a twofold increase in HMG-CoA reductase activity (choles-
terol synthesis), an increase which is coupled with a twofold increase in
cholesterol 7a-hydroxylase activity (bile acid synthesis). The contribution of
altered hepatic cholesterol metabolism to the elevated serum cholesterol
levels observed in renal failure, and the net effect of increase of activity of
these two enzymes on hepatic cholesterol homeostasis have not been ascer-
tained in this study.
Chronic renal disease is associated with a number of abnormal-
ities of lipid metabolism [1—7]. Hypertriglyceridemia is observed
in 20 to 70% of dialyzed and non-dialyzed patients with chronic
renal disease [7]. Previous findings suggest that alteration of
triglyceride metabolism occurs as a result of impaired removal of
very low density lipoprotein (VLDL) [8]. However, other lipopro-
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tein abnormalities have also been described in chronic renal
failure including increased lipoprotein production [6], decreased
high density lipoprotein (HDL) cholesterol [9], reduced plasma
lecithin:cholesterol acyltransferase activity (LCAT) [10], a defect
in lipoprotein and hepatic lipases [11, 12], and abnormal lipopro-
tein metabolism associated with low insulin levels [13]. While
hypertriglyceridemia is the major lipid abnormality in chronic
renal failure, elevation of serum cholesterol levels has also been
reported [6]. The association of hyperlipidemia of chronic renal
disease and accelerated atherosclerosis has generated a continued
interest in the pathophysiology of this association.
Under normal circumstances, the liver is the principle organ
responsible for the maintenance of total body cholesterol ho-
meostasis. The contribution of abnormal hepatic cholesterol
metabolism to the pathogenesis of hypercholesterolemia in
chronic renal failure has not been thoroughly studied. Under
physiologic circumstances, cholesterol homeostasis in the liver is
maintained by a coordinate regulation of HMG-CoA reductase,
the rate limiting enzyme in the cholesterol biosynthetic pathway,
cholesterol 7cr-hydroxylase, the rate-limiting enzyme in the bile
acid biosynthetic pathway, acyl CoA:cholesterol acyltransferase
(ACAT), the enzyme which esterifies free cholesterol, cholesteryl
ester hydrolase (CEH), an enzyme which hydrolyzes cholesterol
esters, the low density lipoprotein (LDL) receptors, responsible
for removal of tissue cholesterol [14], and biliaiy cholesterol
secretion, which represents about 50% of cholesterol removed
each day [15].
The main objective of the present study was to establish
whether alterations of hepatic cholesterol metabolism occur in the
early phase of renal failure. We first established that subtotal
nephrectomy resulted in elevation of serum triglycerides and
cholesterol levels, the two major abnormalities observed in pa-
tients with renal failure. Next, we examined the behavior of
HMG-CoA reductase and cholesterol 7cr-hydroxylase, the two
enzymes which determine the rates of cholesterol synthesis and
degradation. We found that the specific activities of HMG-CoA
reductase and cholesterol 7cr-hydroxylase were increased two to
three fold and that up-regulation of both of these enzymes
occurred at the post-transcriptional level. The net effect of these
changes of hepatic lipid metabolism on cholesterol homeostasis
has not been ascertained in this study.
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Methods
Dithiothreitol, EDTA, proteinase K, ribonuclease A, NADP,
NADPH, isocitrate dehydrogenase, Na-isocitrate, glucose-6-phos-
phate, glucose-6-phosphate dehydrogenase, and 3-hydroxy-3-methyl-
glutaryl coenzyme A were obtained from Sigma Chemical Company
(St. Louis, Missouri, USA). Taurocholic acid (TCA) and cholesterol
oxidase were purchased from Calbiochem (La Jolla, California,
USA). The nick translation kit was obtained from Bethesda Re-
search Laboratories and guanidine thiocyanate was purchased from
Fluka (Ronkonkoma, New York, USA). Deoxyribonuclease I was
obtained from Worthington (Freehold, New Jersey, USA), and
Sephadex G 50, fine, DNA grade was purchased from Pharmacia
(Piscataway, New Jersey, USA). [a-32P] dCTP (3000 Ci/mmol),
[a-32P] GTP (800 Ci/mmol), [4-14C] cholesterol (59.4 mCi/mmol),
DL-[3H]-3-hydroxymethyl-3-glutaiyl coenzyme A (57,6 mCi/mmol),
and DL-[3H] mevalonate (30 Ci/mmol) were all purchased from New
England Nuclear (Boston, Massachusetts, USA). All other reagents
were of the highest quality available. Silica gel thin-layer chromatog-
raphy plates were obtained from Fisher Scientific (Pittsburgh, Penn-
sylvania, USA). Intramedic polyethylene tubing (P-SO) and Dow
Corning silastic tubing were obtained from American Scientific.
cDNA used were: (1) EcoRl-Acci fragment of plasmid pBSK 7a6
which contains a cholesterol 7cs-hydroxylase c-DNA was a gift of
John Chiang [8]; (2) HMG-CoA reductase insert of plasmid pRED
227 (American Type Culture Collection, Rockville, Maryland, USA);
(3) LDL plasmid insert (a gift from Roger A. Davis [16]; (4) albumin
cDNA insert of plasmid pRSA 57 (American Type Culture Collec-
tion); and cyclophilin insert of plasmid plBl5 [20].
75% Nephrectomy (uremic) rat model
Male Sprague-Dawley rats (Charles River, Cambridge, Massa-
chusetts) weighing between 150 and 200 g were housed under
controlled lighting conditions on a natural light-dark cycle (0600-
1800 light phase). Groups of age- and weight-matched animals
were used in all experiments. Surgeries were performed in two
stages using methoxyfiurane anesthesia. On day 0, the left kidney
was exposed and decapsulated in all rats. The upper and lower
thirds of the organ were excised in the nephrectomy group only.
On day 7, the right kidney was exposed and decapsulated in all
rats and excised in the nephrectomy group only. After surgery,
animals were placed in individual metabolic cages with free access
to water and laboratory chow. All rats were pair fed, receiving the
same diet, powdered rat chow modified to contain 35.3% casein.
Protein supplementation was provided to exacerbate the uremic
state in nephrectomy animals while ensuring normal protein
intake in sham operated controls. Animals were sacrificed by
decapitation on day 21 after second surgery. Just prior to sacrifice,
under brief methoxyflurane anesthesia, biliary cannula were
placed and a 20 minute collection of bile was obtained for analysis
of biliary bile acid, cholesterol, and phospholipid secretion. At the
conclusion of the experiment, animals were sacrificed (between 9
and 10 a.m.), livers were harvested and four one gram pieces were
removed. Two pieces were used to extract total RNA, and two
pieces to isolate nuclei. The remainder of the liver was used in the
preparation of microsomes as previously described [16].
Determinations of serum parameters
Laboratory values for blood urea nitrogen and serum choles-
terol, triglycerides, albumin, aspartate aminotransferase (AST),
Table 1. Effect of 75% nephrectomy on animal weights as compared to
sham operated controls
Weight in grams
Prior to
N Pre-op sacrifice Weight gain
Controls 8 175.0 5.2 290.6 8.2 115.6 10.6
Uremics 8 178.6 2.4a 261.6 boa 82.9 9.8a
Data expressed as mean SE.
a No statistical significant difference from control values
and alanine aminotransferase (ALT) were determined in the
clinical laboratory at the Veterans Administration Hospital in
Richmond, Virginia, USA.
Assays for HMG-CoA reductase and cholesterol 7a-hydroxylase
specific activity
Microsomal HMG-CoA reductase specific activity was assayed
by the method of Whitehead et al [17]. The specific activity of
cholesterol 7cs-hydroxylase was determined in microsomes using a
high performance liquid chromatography (HPLC) assay proce-
dure as described previously by us [18].
Determination of mRNA levels and transcriptional activity for
HMG-CoA reductase, cholesterol 7c-hydroxylase, and low density
lipoprotein receptor
Methods used for the isolation of mRNA and hepatic nuclei
have been recently described in great detail as have our tech-
niques for dot blot hybridization and nuclear run-on assays [191.
The absorbencies for hybridization to cholesterol 7o-hydroxy-
lase (pBSK 7a6), HMG-CoA reductase (pRED 227), and low
density lipoprotein receptor (LDL-R) as standardized to albumin
pRSA 57 were determined for each condition, and the resulting
indices were compared to the control animals. In order to insure
that albumin transcriptional activity was unaffected by experimen-
tal manipulation (75% nephrectomy), albumin transcriptional
rates were also standardized to cyclophilin (plBl5). Cyclophilin is
a cytosolic protein which binds cyclosporin [20]. No differences in
the transcriptional activity of albumin was noted between the
control and uremic state when standardized to cyclophilin.
Determination of microsomal cholesterol
Microsomal free cholesterol was determined by the method of
Abell et al [21].
Statistical analysis
Statistical differences between groups were tested by means of
Students's t-test for unequal samples.
Results
Effect of 75% nephrectomy on animal weight gain
Mean pre- and end-study animal weights were not significantly
different in control versus 75% nephrectomy animals (Table 1).
Both control rats and nephrectomized rats ate similar quantities
of chow and had almost identical weight gain suggesting that
experimental rats completed the study in a good nutritional state.
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Table 2. Effect of 75% nephrectomy on the following laboratory
parameters as compared to sham operated control values
Uremic values
% of
N control P
Serum values
Blood urea nitrogen 7 371 44 <0.001
Triglycerides 4 185 25 <0.01
Cholesterol 7 133 7 <0.005
Albumin 4 88 3 NS
Ast 4 101±8 NS
Alt 4 94±9 NS
Microsomal values
Cholesterol (free) 8 150 13 <0.01
Data are expressed as mean SE. Abbreviations are: Ast, aspartate
aminotransferase; Alt, alanine aminotransferase; and NS, no statistical
significant difference.
Table 3. Effect of 75% nephrectomy on biliary lipids as compared to
sham operated controls
Uremic values
% of
N control P
Bile flown 8 110±6%
Bile acid concentrationb 8 132 28%
Biliary cholesterol secretionc 8 166 13%
Biliary phospholipid secretiond 8 201 31%
NS
NS
<0.01
<0.03
Data are expressed as the mean SE. NS is no statistical significant
difference.
Mean control values: 0.83 0.06 ml/hr; b 32.7 6.3 mol/ml; C 0.38
0.04 .rmol/hr-100 g rat; ' 0.16 0.03 xmol/hr-100 g rat
Effect of 75% nephrectomy on blood urea nitrogen, serum
cholesterol, triglycerides, albumin, aspartate aminotransferase
(Ast), and alanine aminotransferase (Alt)
Table 2 demonstrates that 75% nephrectomy led to a 371%
increase in the blood urea nitrogen (P < 0.001), 185% increase in
serum triglyceride values (P < 0.005), and a 133% increase in
serum cholesterol (P < 0.01). Microsomal cholesterol was also
markedly increased (150 13%) over controls (P < 0.01). Serum
albumin, aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) were not significantly different from controls.
These experiments show these elevations of plasma lipids occur
without any evidence of gross liver injury.
Effect of 75% nephrectomy on bile flow, bile acid concentration,
and biliaiy cholesterol and phospholipid secretion
At the conclusion of the study, a 20 minute collection of bile
was obtained for analysis of bile flow and biliary lipid composition
(Table 3). Bile flow and bile acid concentration in rats that had
undergone 75% nephrectomy were not significantly different from
sham operated controls. In rats with subtotal nephrectomy, cho-
lesterol and phospholipid secretion increased by 166 13% and
201 31%, respectively. These differences were statistically
significant (P < 0.01 and P < 0.03).
Table 4. Effect of 75% nephrectomy on HMG-CoA reductase
cholesterol 7a-hydroxylase and LDL receptor as compared to sham
operated control values
N
Specific
activity
mRNA
levels
Transcription
activity
% of control
HMG-CoA-R 8 219 30 109 11 104 17
P <0.02 NS NS
C7aH 8 240 55 93 8 56 8
P <0.05 NS <0.01
LDL receptor 8 — 86 15 94 3
P NS NS
Data are expressed as the mean SE. Abbreviations are: HMG-CoA-R,
HMG-CoA reductase; C7aH, cholesterol 7a-hydroxylase; LDL, low den-
sity lipoprotein receptor; NS, no statistical significant difference.
Mean control values for HMG-CoA-R and C7csh specific activities are
1.48 0.34 and 0.587 .17 nmol/hr-mg of microsomal protein, respec-
tively.
Effect of 75% nephrectomy on the specific activities, steady-state
mRNA levels, and transcriptional activities of HMG-CoA
reductase, cholesterol 7a-hydroxylase, and of the low density
lipoprotein receptor activity
A 2.2-fold increase (P < 0.02) in the specific activity of
HMG-CoA reductase and a 2.4-fold increase (P < 0.05) in
cholesterol 7a-hydroxylase specific activity were observed in ne-
phrectomized (uremic) rats as compared to sham operated con-
trols (Table 4). Steady-state mRNA levels were quantitated using
total RNA (0.6 to 10 gig) blotted onto nitrocellulose membranes,
as previously described in detailed by Pandak et al [19]. HMG-
CoA reductase and cholesterol 7a-hydroxylase steady-state
mRNA levels by dot blot analysis (Fig. 1 and Table 4) were not
significantly different from sham operated controls. As described
in the Methods section, the absorbencies for hybridization to
HMG-CoA reductase, cholesterol 7cs-hydroxylase and LDL re-
ceptor as compared to albumin were determined for each condi-
tion, and the resulting indices were compared to the control
animals.
Figure 2 demonstrates a representative nuclear run-on assay for
cholesterol 7a-hydroxylase (line A), HMG-CoA reductase (line
C), and albumin (line B). The ratio of transcriptional activity of
the HMG-CoA reductase and LDL (Table 4) to that of the
albumin gene was not significantly altered by 75% nephrectomy.
However, 75% nephrectomy led to a 44% decrease (P < 0.01) in
the transcriptional activity of cholesterol 7cs-hydroxylase as com-
pared to controls.
The nuclear run-on assay is an accepted and frequently used
method to estimate gene transcriptional activity. The assay re-
fleets transcriptional activity in vivo. In the nuclear run-on assay
nascent RNA transcripts are allowed to elongate in the presence
of nucleotides of which one is labeled with [a-32P]. In order to
account for variations in [32P] uptake and incorporation by the
nuclei, number of nuclei, and amount of labeled nucleotide
added, the RNA transcripts were also hybridized to albumin
(pRSA) and cyclophilin (plBl5), which serves as an internal
control. The comparison of the transcriptional activity of the gene
of interest with an appropriate standard is a routine practice when
determining transcriptional activity. The in vivo transcriptional
activity is calculated from cholesterol 7cs-hydroxylase/albumin
ratio by laser densitometry over the range of concentrations.
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Fig. 1. Representative dot blot hybridization of HMG-CoA reductase and cholesterol 7a-hydroxylase mRNA. a. J-IMG-CoA reductase; b, cholesterol
7a-hydroxylase; and c, albumin. Total RNA was isolated from livers of animals with 75% nephrectomy vs. that of sham operated controls. Varying
amounts (10 to 0.6 j.g) of total RNA were spotted unto nitrocellulose membrane filters and probed with cholesterol 7a-hydroxylase cDNA as described
under Methods. This probe was stripped and then reprobed with eDNA for albumin and HMG-CoA reductase. Shown are representative blots for
HMG-CoA reductase, cholesterol 7a-hydroxylase and albumin, demonstrating the effects of 75% nephrectomy (U) vs. sham operated controls (C).
A B C
Fig. 2. Effect of 75% nephrectomy on cholesterol 7a-hydroxylase (A),
HMG-CoA reductase (C), and albumin (B) transcriptional activity as
determined in isolated hepatic nuclei. Nuclei were isolated from the livers of
rats with 75% nephrectomized and sham operated controls. Nascent RNA
transcripts were allowed to elongate in the presence of bs-32P1 GTP.
32P-labeled RNA was then isolated and hybridized to 5 g amounts of
cDNA from HMG-CoA reductase, cholesterol 7n-hydroxylase or albumin
as described in the Methods. Relative amounts of RNA hybridizing to
probe were then quantified by laser densitometer. Absorbencies for
hybridization to cholesterol 7a-hydroxylase (pBSK 7n6) and HMG-CoA
reductase (pRED 227) were standardized to albumin (pRSA 57). Shown
are representative blots demonstrating the effects of 75% nephrectomized
rats vs. sham operated controls.
The absorbance values of cholesterol 7a-hydroxylase and albumin
were plotted separately and the slopes were then calculated. The
intensity of dot blots in individual experiments cannot be used solely
as a measure of quantitation; it is the ratio of cholesterol 7a-
hydroxylase (or HMG-CoA reductase) to that of albumin (pRSA 57)
Fig. 3. Effect of 75% nephrectomy on the specific activities (a), steady-state
mRNA levels (U) and in vitro transcription rates of HMG-CoA reductase,
cholesterol 7a-hydroxylase, and LDL receptor (n). Composite data for rats
that underwent 75% nephrectomy is displayed in graphic form expressed
as the % of sham operated control values (100%). Specific activity, mRNA
levels, and transcriptional activity were determined as outlined under
Methods. Values shown are the mean SE. N = 8 for HMG-CoA
reductase and cholesterol 7a-hydroxylase, and 4 for LDL receptor (LDL).
or cyclophilin (plBl5) that yields the quantitation of mRNA or gene
transcription.
Figure 3 demonstrates a composite of specific activities, steady-
state levels of mRNA and the transcriptional activities of HMG-
CoA (HMG-R) and cholesterol 7n-hydroxylase (C7csH) ex-
pressed as percent control. There was a twofold increase in
HMG-CoA reductase and cholesterol 7a-hydroxylase activities
which was not coupled with parallel increases of steady-state
a
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levels of mRNA or transcriptional activity. In the case of choles-
terol 7a-hydroxylase, transcriptional activity was decreased by
44%.
Discussion
There is a growing awareness that hyperlipidemia in several
types of renal disease represents a significant risk factor for
coronary heart disease [22].A classical example of this association
are patients with nephrotic syndrome, who develop marked
hypercholesterolemia relatively early in the course of their disease
[23]. Recently, these patients have been shown to have elevated
levels of Lp(a) lipoprotein which has thrombogenic and athero-
genic properties [24]. For these reasons, the reduction of hyper-
cholesterolemia in the nephrotic syndrome has been an important
therapeutic goal, as elevated cholesterol levels appear to be
associated with worsening of renal and coronary heart disease.
Indeed, in the nephrotic syndrome, administration of lovastatin
resulted in prevention of glomerulosclerosis and uremia [26].
In contrast to nephrotic syndrome, chronic renal failure in
humans is associated with marked increases in serum total
triglycerides and very low density lipoproteins [1, 6]. The hyper-
triglyceridemia found in patients with chronic renal disease has
been attributed to defective lipoprotein clearance [27—29], which
is thought to occur as a result of a decrease in lipoprotein and
hepatic lipases, and in the plasma activity of lecithin:cholesterol
acyltransferase [10—12]. These patients were also described to
have somewhat less pronounced abnormalities of cholesterol
metabolism manifested as hypercholesterolemia [6], and a de-
crease in total high density apoprotein (HDL) and HDL2 choles-
terol levels [30, 31]. The mechanism responsible for hypercholes-
terolemia in chronic renal disease has not been clearly defined
and changes in hepatic cholesterol metabolism have not been
systematically studied. The present study was designed to provide
information on the effects of renal failure on hepatic cholesterol
metabolism.
Partially nephrectomized rats have been previously used to
study various metabolic alterations in chronic renal failure [32—
34]. In the present study, partially nephrectomized rats ate
normally and gained weight while developing chronic renal failure
manifested by a fourfold increase in blood urea nitrogen. After
three weeks, rats with subtotal nephrectomy demonstrated a
marked increase in serum triglyceride and cholesterol levels,
suggesting that this experimental model could be used to simulate
chronic renal failure in humans. As in chronic renal failure,
elevation of serum triglycerides was more pronounced than
elevation of serum cholesterol.
The results of the present study demonstrate that HMG-CoA
reductase specific activity, which is often taken as an index of
cholesterol synthesis, was increased more than twofold in rats with
partial nephrectomy and uremia. This was a surprising observa-
tion since in the presence of elevated levels of serum cholesterol
and increased hepatic microsomal cholesterol concentration, the
HMG-CoA reductase specific activity would be expected to be
suppressed rather than stimulated [35]. Thus, it appears that
normal feedback regulation of HMG-CoA reductase is altered in
partially nephrectomized rats with induced renal failure. HMG-
CoA reductase steady-state levels of mRNA and gene transcrip-
tional activity were unchanged as compared to controls. These
findings suggest that in the experimentally induced renal failure in
the rat, the observed increase in HMG-CoA reductase specific
activity may be due to an alteration in enzyme catalytic activity,
that is, altered phosphorylation-dephosphorylation [36—38] or
changes in the membrane fluidity [39]. These data are consistent
with observations of Ness, Keller and Pendelton [40] who have
recently reported that in the rat, feedback regulation of HMG-
CoA reductase by dietary cholesterol may not be due to altered
mRNA levels as previously thought. However, even in that study
the specific activity of HMG-CoA reductase was suppressed by
cholesterol. Therefore, the findings of the present study suggest
that in renal failure there is an alteration of feedback regulation
of HMG-CoA reductase. Alternatively, these changes could be
due to alteration in protein synthesis and/or degradation.
Bile acid synthesis from cholesterol is a major pathway for
elimination of cholesterol from the body. Approximately, 50% of
cholesterol eliminated from the body each day is catabolized in
the liver to primary bile acids via a number of intermediary steps.
The remaining cholesterol is removed from the body via canalic-
ular secretion of cholesterol [13]. Cholesterol 7a-hydroxylase, a
cytochrome P-450 monooxygenase is located in the hepatocyte
smooth endoplasmic reticulum. This enzyme has been recently
purified, characterized and cloned by several investigators, pro-
viding for the first time, the opportunity to study molecular basis
of its regulation under physiologic and pathophysiologic circum-
stances [41—43]. The major physiologic regulators of cholesterol
7n-hydroxylase activity appear to be cholesterol [19], certain
hormones such as dexamethasone and thyroxine [44] and hydro-
phobic bile salts [45—47], all acting at the level of gene transcrip-
tion [19, 48].
Under physiologic and pharmacologic conditions, HMG-CoA
reductase and cholesterol 7o-hydroxylase specific activities change in
tandem as if they are responding to the same regulatory signal [14,
47]. The increase in HMG-CoA reductase specific activity appears to
precede the increase in cholesterol 7a-hydroxylase activity. This
latter finding suggests that the newly synthesized cholesterol may
play a role in the regulation of cholesterol 7a-hydroxylase. These
conclusions were recently confirmed by Pandak et al [19], who have
shown that inhibition of cholesterol synthesis with lovastatin results
in a prompt and profound down-regulation of cholesterol 7a-
hydroxylase activity. This effect can be prevented by a continuous
infusion of mevalonate, a precursor of cholesterol. Furthermore,
Jones et al [49] have recently shown that infusion of mevalonate
increases cholesterol 7s-hydroxylase steady-state mRNA and tran-
scriptional activity, while a single injection of lovastatin, a competitive
inhibitor of HMG-CoA reductase, decreases cholesterol 7a-hydrox-
ylase mRNA and transcriptional activity. The data obtained in the
present study indicate that in uremia, the interrelationship between
cholesterol and bile acid synthesis is maintained, that is, both
appeared to be increased to a similar extent. The increase in
cholesterol 7a-hydroxylase activity (bile acid synthesis) is most likely
driven by increased availability of newly synthesized cholesterol,
which appears to be a major regulator of this enzyme. Since the
observed magnitude of increases in HMG-CoA reductase and cho-
lesterol 7a-hydroxylase specific activities were almost identical, one is
tempted to speculate that most of the newly synthesized cholesterol
is converted to bile acids rather than diverted to the formation of very
low density lipoproteins. Interestingly, the specific activities of both
enzymes were increased in the presence of unaltered mRNA and
normal or decreased gene transcriptional activity. In this regard, the
mechanism of regulation of cholesterol 7n-hydroxylase in renal
failure departs from experimental findings in normal rats, in which
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the enzyme is up-regulated by cholesterol at the transcriptional level
[48]. The additional factor(s) responsible for these differences in the
regulation of cholesterol 7cv-hydroxylase have not been identified in
this study.
In summary, we have provided evidence that in early renal
failure, the specific activities of HMG-CoA reductase and choles-
terol 7a-hydroxylase are increased twofold. The primary event
appears to be a paradoxical increase in HMG-CoA reductase
specific activity. Almost identical increases in cholesterol 7cs-
hydroxylase activity are likely caused by the availability of newly
synthesized cholesterol.
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